VERA Vera Therapeutics, Inc.

NASDAQ

$32.54

Vera Therapeutics, Inc. (VERA) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $1.72 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.8% since its last earnings release on August 10, 2026.

Vera Therapeutics Beat Consensus Estimates

Monday, August 10, 2026 · 4:05 PM ET

3rd Quarter, Sep 2026

Monday · Before Open

Earnings Whisper

-

vs ($1.72)

Rev est $2.62M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $33.53

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vera Therapeutics, Inc.

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.